Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Hill

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
American Journal of Respiratory and Critical Care Medicine|August 9, 2023
A Randomized Controlled Clinical Trial of Nasal Immunization with Live Virulence Attenuated <i>Streptococcus pneumoniae</i> Strains Using Human Infection ChallengeHelen Hill, Elena Mitsi, Elissavet Nikolaou, et al.
American Journal of Respiratory and Critical Care Medicine|July 8, 2022
Human Infection Challenge with Serotype 3 PneumococcusRyan E Robinson, Elena Mitsi, Elissavet Nikolaou, et al.
Cell Reports|May 26, 2026
Host-microbial interactions at the nasal mucosa in young children and adults: A retrospective, cross-sectional studyJesús Reiné, Lisa A King, Youvika Singh, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
JAMA|September 3, 2020
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical TrialDerek C Angus, Lennie Derde, Farah Al-Beidh, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
American Journal of Respiratory and Critical Care Medicine|August 9, 2023
A Randomized Controlled Clinical Trial of Nasal Immunization with Live Virulence Attenuated <i>Streptococcus pneumoniae</i> Strains Using Human Infection ChallengeHelen Hill, Elena Mitsi, Elissavet Nikolaou, et al.
American Journal of Respiratory and Critical Care Medicine|July 8, 2022
Human Infection Challenge with Serotype 3 PneumococcusRyan E Robinson, Elena Mitsi, Elissavet Nikolaou, et al.
Cell Reports|May 26, 2026
Host-microbial interactions at the nasal mucosa in young children and adults: A retrospective, cross-sectional studyJesús Reiné, Lisa A King, Youvika Singh, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
JAMA|September 3, 2020
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical TrialDerek C Angus, Lennie Derde, Farah Al-Beidh, et al.
Pageof 4